

The pursuit of tuberculosis (TB) elimination is often depicted as a final sprint. In 2024, 62 countries reported a low TB incidence (<10 cases per 100,000 population).1 This commentary addresses a crucial challenge: the inherent fragility of progress in these settings, where hard-won gains can prove unexpectedly vulnerable to reversal.
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet
Regional Health – Americas
|11th Mar, 2026
|The Lancet